Testing diabetes heart medicine soon after a heart attack
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study looks at how starting an SGLT2 inhibitor (a diabetes medicine) around the time of a heart attack affects heart outcomes and heart muscle changes over time. It may help you and your care team understand whether this timing is beneficial after a PCI procedure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a heart attack (acute myocardial infarction) and were treated with PCI
- You have type 2 diabetes
- You started an SGLT2 inhibitor within 1 month before or after your PCI
- You have not used SGLT2 inhibitors before starting this study medicine
- You are not pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving an SGLT2 inhibitor (a diabetes medicine that may also protect the heart) early after a heart attack can help shield the heart from damage. It is for people having a first-time STEMI heart attack who have adequate kidney function and stable blood pressure.
This trial studies how diabetes medicines (GLP-1 and SGLT2, alone or together) affect the heart in people with type 2 diabetes who are at higher cardiovascular risk and have heart failure with preserved pumping function. It may help find safer or more effective ways to reduce heart problems.
This trial tests whether a diabetes drug called dapagliflozin (also used for heart failure) can help people recover better after a recent heart attack. It's for adults who are already on standard blood thinners and have had a heart attack in the past week.
This trial studies whether starting an SGLT-2 inhibitor around the time of a heart attack can reduce heart damage size and improve how the heart heals. It focuses on people with a high risk of developing heart failure and who are getting a procedure to open blocked heart arteries.
This study looks at whether certain diabetes medicines, called SGLT2 inhibitors and GLP-1 receptor agonists, can help protect the heart in people with type 2 diabetes. It may help you understand if these treatments are a good option for your heart health.
This study tests whether a diabetes medication called ertugliflozin can help protect your heart function after a heart attack. Researchers want to see if starting this medicine early (within 3 days) helps your heart recover better.
Hear when a new Myocardial Infarction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.